Effect of the Sodium-Glucose Cotransporter 2 Inhibitor Canagliflozin for Heart Failure With Preserved Ejection Fraction in Patients With Type 2 Diabetes
Tomoya Ueda, Shu Kasama, Masahiro Yamamoto, Tomoya Nakano, Kazuhiro Ueshima, Yoshinobu MORIKAWA, Hiroyuki Kawata, Akiomi Yoshihisa, Masafumi Nakayama, Sei Komatsu, Tsunenari Soeda, Makoto Watanabe, Rika Kawakami, Yasushi Okada, Hiroyuki Tanaka, Yutaka Susuta, Masato Kasahara, Kenichi Tsujita, Yasuchika Takeishi, Yoshihiko Saito, CANONICAL Study Group
Abstract
In this study, canagliflozin treatment reduced BW, but did not significantly reduce plasma BNP concentrations compared with standard therapy after 24 weeks treatment in T2D patients with HFpEF. Further large-scale randomized studies are needed to conclude the beneficial effects of canagliflozin in T2D patients with HFpEF.
Topics & Concepts
CanagliflozinType 2 diabetesEjection fractionInternal medicineEndocrinologyMedicineHeart failureSodiumDiabetes mellitusChemistryPharmacologyOrganic chemistryDiabetes Treatment and ManagementPotassium and Related DisordersHeart Failure Treatment and Management